Intratumor morphologic and molecular genetic heterogeneity in astrocytomas of different grade of malignancy in the material from the first operation

Autor: D. E. Matsko, M. V. Matsko, A. O. Baksheeva, E. N. Imyanitov, A. Yu. Ulitin, V. M. Moiseenko, K. V. Shelekhova, N. M. Volkov, A. G. Ievleva, V. I. Tiurin, S. S. Sklyar, A. A. Zrelov, A. S. Morozova

Publikováno v: Сибирский онкологический журнал, Vol 20, Iss 6, Pp 55-68 (2022)

Introduction. Intratumor heterogeneity is one of the key reasons for unfavourable prognosis in malignant tumors. Astrocytic tumors are known to develop therapy resistance inevitably during the course of disease. One of possible reason is tumor hetero

Externí odkaz: https://doaj.org/article/450d04d7a67f403cadbf4240b2d8449c

EMBRYONAL TUMORS OF THE CENTRAL NERVOUS SYSTEM IN ADULTS: A REPORT OF THREE CASES. REVIEW OF THE LITERATURE

Autor: M. V. Matsko, D. E. Matsko, E. N. Imyanitov, S. S. Sklyar, A. Yu. Ulitin, I. V. Yakovenko, A. G. Ievleva, G. A. Ershov, A. A. Romanko, A. S. Nechaeva

Publikováno v: Сибирский онкологический журнал, Vol 20, Iss 1, Pp 105-114 (2021)

Background. Еmbryonal tumors of the central nervous system are malignant neoplasms that mainly occur in pediatric patients with a peak incidence at the age of 4 years. These tumors usually have small round blue cell histology and low differentiation

Externí odkaz: https://doaj.org/article/52d6446c8fa241eb98f87b2bf2567485

COST-EFFICACY ANALYSIS OF GEFITINIB EFFICACY IN PATIENTS WITH NON OPERABLE NON SMALL CELL LUNG CANCER

Autor: S. A. Protsenko, A. V. Rudakova, F. V. Moiseyenko, E. V. Levchenko, D. E. Matsko, A. О. Ivantsov, I. I. Semenov, A. G. Ievleva, N. V. Mitushkina, A. V. Togo, A. V. Novik, E. N. Imyanitov, V. M. Moiseyenko

Publikováno v: Креативная хирургия и онкология, Vol 0, Iss 2, Pp 46-52 (2017)

Drug treatment of disseminated non small cell lung cancer (NSCLC) is an actual issue today. Both clinical and economic efficacy analysis is needed for optimal therapy selection. We performed economic efficacy assessment of gefitinib (G.) therapy in p

Externí odkaz: https://doaj.org/article/e5b353add05b45ec86743eaa42e6c519

Clinical and morphological features of breast tumors with PIK3CA mutations in Russian patients: Observational study

Autor: Tatyana N. Sokolova, Tatyana I. Solov'eva, Svetlana N. Aleksakhina, Grigorii A. Janus, Alla Goryainova, Mark I. Gluzman, Rashida V. Orlova, Anastasiya I. Stukan, Ruslan A. Zukov, Alena V. Zyuzyukina, Yulia N. Murunova, Aleksandr V. Sultanbaev, Elena N. Vorobeva, Leonid M. Mikhaevich, Victoria N. Pyliv, Anna N. Lysenko, Zarema K. Khachmamuk, Andrey E. Kozlov, Sergey Y. Bakharev, Shahen G. Parsyan, Elena I. Rossokha, Leri D. Osidze, Irina S. Shumskaya, Anna V. Agaeva, Tatiana A. Kasmynina, Veronika V. Klimenko, Kamila T. Akhmetgareeva, Almira A. Vakhitova, Madina D. Chakhkieva, Vadim N. Dmitriev, Yana I. Bakshun, Alexey E. Vasilyev, Dunya D. Gasimly, Nadezhda A. Kravchenko, Dmitriy A. Maksimov, Alfia I. Nesterova, Ineza O. Sharvashidze, Christina H. Gadzaova, Galina G. Rakhmankulova, Zaur M. Khamgokov, Irina K. Amirkhanova, Ludmila V. Bembeeva, Vladimir I. Vladimirov, Oleg L. Petrenko, Natalia G. Ruskova, Ekaterina L. Serikova, Ksenia S. Subbotina, Svetlana A. Tkachenko, Victor L. Chang, Sanal P. Erdniev, Victoria S. Barbara, Anna V. Vasilevskaya, Yulia V. Mikheeva, Nataliya O. Popova, Ekaterina P. Startseva, Anastasia V. Fateeva, Denis Y. Yukalchuk, Anna A. Grechkina, Khedi S. Musaeva, Svetlana V. Odintsova, Alena S. Stel'makh, Petimat I. Khabibulaeva, Alina G. Khlobystina, Kseniya A. Shvaiko, Elena A. Basova, Irina A. Bogomolova, Marina B. Bolieva, Viktor E. Goldberg, Marianna V. Kibisheva, Konstantin V. Menshikov, Dmitrii V. Ryazanov, Mariya L. Stepanova, Yana A. Udalova, Aleksandr V. Shkradyuk, Yana S. Chapko, Anna A. Shchukina, Idris M. Khabriev, Dmitrii V. Kirtbaya, Alexey M. Degtyarev, Aleksandr A. Epkhiev, Yana A. Tyugina, Mirza A. Murachuev, Aleksandr V. Togo, Aglaya G. Ievleva, Evgenii N. Imyanitov

Publikováno v: Современная онкология, Vol 24, Iss 1, Pp 12-23 (2022)

Background. By 2020, breast cancer (BC) has become the most frequent malignancy in the world. The most common type of BC is HR+/HER2-negative cancer,2540% of which harbors PIK3CA mutations that affect the catalytic subunit of the PI3K protein. PIK3CA

Externí odkaz: https://doaj.org/article/ac2dc051d6cd4d1686520ce6a60f66af

Primenenie Iressy (gefitiniba)v kachestve terapii pervoy liniidlya lecheniya neoperabel'nykhadenokartsinom legkogo, soderzhashchikhmutatsiyu v gene EGFR

Autor: V M Moiseenko, S A Protsenko, I I Semenov, F V Moiseenko, E V Levchenko, D E Matsko, A O Ivantsov, A G Ievleva, N V Mityushkina, A V Togo, E N Imyanitov

Publikováno v: Современная онкология, Vol 12, Iss 1, Pp 60-66 (2010)

Externí odkaz: https://doaj.org/article/17cba73991ce46baae6710e5a4cb683e